The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|September 3, 2013
BioReliance Updates Big Blue Mouse Assay Service
Author(s)Pharmaceutical Technology Editors
BioReliance updates Big Blue Mouse Assay service to meet OECD test requirements.
Advertisement
RELATED ARTICLES
BioReliance
, SAFC’s biologics and early-development services business, has qualified the Big Blue Mouse Transgenic Rodent Mutation (TRM) assay to meet the new Organization for Economic Co-Operation and Development (OECD) Test Guideline 488 requirements for evaluation of
in vivo
mutagenicity.
Big Blue is identified in OECD Test Guideline 488 and recommended by the European Chemicals Agency as an accepted assay for evaluating mutagenicity in somatic and male germ cell tissues.
BioReliance acquired the exclusive ownership of the Big Blue TRM assay and rodents from Agilent in March 2013.
Source:
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement